2196 — Shanghai Fosun Pharmaceutical Co Balance Sheet
0.000.00%
- HK$32.95bn
- HK$67.64bn
- CNY41.40bn
- 28
- 66
- 28
- 32
Annual balance sheet for Shanghai Fosun Pharmaceutical Co, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | CAS | CAS | CAS | CAS | CAS |
Status: | Final | Final | Final | Final | Final |
Cash | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 9,990 | 10,939 | 13,582 | 16,937 | 15,326 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 5,947 | 6,376 | 8,037 | 9,135 | 9,697 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 20,403 | 25,085 | 30,425 | 35,279 | 33,793 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 11,430 | 13,258 | 14,445 | 17,395 | 23,671 |
Net Goodwill | |||||
Net Intangible Assets | |||||
Long Term Investments | |||||
Long Term Notes Receivable | |||||
Other Long Term Assets | |||||
Total Assets | 76,120 | 83,686 | 93,294 | 107,164 | 113,470 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 17,434 | 24,872 | 29,310 | 33,298 | 33,758 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Deferred Income Tax | |||||
Minority Interest | |||||
Total Other Liabilities | |||||
Total Liabilities | 44,232 | 46,690 | 54,102 | 62,581 | 67,785 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Treasury Stock | |||||
Unrealized Gain / Loss | |||||
Other Equity | |||||
Total Equity | 31,888 | 36,996 | 39,192 | 44,582 | 45,685 |
Total Liabilities & Shareholders' Equity | 76,120 | 83,686 | 93,294 | 107,164 | 113,470 |
Total Common Shares Outstanding |